Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

34P - Patient characteristics and treatment patterns in advanced renal cell carcinoma (aRCC): Following introduction of new therapies

Date

09 Dec 2020

Session

e-Poster Display Session

Presenters

Yousef Zakharia

Citation

Annals of Oncology (2020) 31 (suppl_7): S1428-S1440. 10.1016/annonc/annonc391

Authors

Y. Zakharia1, G. Zanotti2, F. Liu3, R. Levin2, A. Meche2

Author affiliations

  • 1 University of Iowa, Iowa City/US
  • 2 Pfizer Inc - USA, New York/US
  • 3 EMD Serono, Rockland/US
More

Abstract 34P

Background

Little research exists on real-world (RW) treatment patterns and outcomes for newly evolving immuno-oncology (IO) combination and targeted therapy regimens recently added to the National Comprehensive Cancer Network (NCCN) guidelines for aRCC. The objective of this study was to characterize patient characteristics and treatment patterns of patients with aRCC treated with IO and tyrosine kinase inhibitor (TKI) monotherapy (mono) and combination (combo) regimens in RW clinical practice.

Methods

This retrospective cohort study of patients with aRCC treated at oncology practices in the US used a Flatiron Health (FH) electronic health record-derived, de-identified database curated to include patients with ≥ 2 RCC ICD codes (ICD-9: 198.x or ICD-10: C64-C65), clinical confirmation of stage IV, and who received pembrolizumab, nivolumab, ipilimumab, atezolizumab, durvalumab, or avelumab in any line. The study included patients on the following FH-curated, first-line (1L) regimens, IO+IO combo, IO mono, TKI mono or IO+TKI combo, initiated between April 2018 and December 2019. Patient characteristics and clinical factors were analyzed descriptively for the above cohorts.

Results

Of 938 patients with aRCC treated with 1L regimens of interest, > 90.0% were treated in community settings. The most prevalent 1L regimen was IO+IO combo, with 441 patients (45.8%). TKI mono represented 185 patients (19.2%), IO+TKI combo, 177 (18.4%), and IO mono, 135 (14.0%). Baseline demographics and clinical factors identified within 60 days of the start of 1L therapy by cohort are described in the table. Table: 34P

Baseline patient demographics and clinical characteristics among 1L aRCC treatment cohorts

IO+IO Combo n= 441 IO Mono n = 135 TKI Mono n = 185 IO + TKI Combo n = 177
Age, years Mean (SD) 65.21 (10.5) 70.66 (10.5) 67.30 (10.1) 65.82 (10.2)
Sex, n (%) F M 112 (25.4) 329 (74.6) 61 (45.2) 74 (54.8) 43 (23.2) 142 (76.8) 60 (33.9) 117 (66.1)
Race, n (%) White Other Unknown Black or Afr Am Asian 291 (66.0) 70 (15.9) 44 (10.0) 30 (6.8) 6 (1.4) 97 (71.9) 11 (8.1) 13 (9.6) 13 (9.6) 1 (0.7) 114 (61.6) 34 (18.4) 18 (9.7) 14 (7.6) 5 (2.7) 113 (63.8) 25 (14.1) 29 (16.4) 10 (5.6) 0 (0)
ECOG, n (%) 0 1 2 ≥3+ 167 (37.9) 126 (28.6) 19 (4.3) 8 (1.8) 41 (30.4) 38 (28.1) 22 (16.3) 1 (0.7) 73 (39.5) 52 (28.1) 9 (4.9) 0 (0) 81 (45.8) 53 (29.9) 14 (7.9) 1 (0)

Conclusions

RW data provide insight into how physicians and patients adapt to new treatment guidelines. These data demonstrate an increase in prescribing of IO+TKI regimens as 1L treatment since their approval in April 2019. Future work will explore outcomes for these new therapies once increased follow-up time is available.

Legal entity responsible for the study

Pfizer, Inc.

Funding

Pfizer, Inc.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.